Federal Register / Vol. 75, No. 43 / Friday, March 5, 2010 / Notices 10285 

Gutkind JS. Proteomic analysis of lasercaptured paraffin-embedded tissues: a 

molecular portrait of head and neck 

cancer progression. Clin Cancer Res. 

2008 Feb 15;14(4)1002–1014. [PubMed: 

18281532]. 

Patent Status: U.S. Provisional 

Application No. 61/186,582 filed June 6, 

2009 (HHS Reference No. E–300–2008/ 

0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Whitney Hastings, 

PhD; 301–451–7337; 

hastingw@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIDCR, OPCB, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize the use of DSG3 as a 

biomarker for detecting metastastatic 

spread of squamous cell carcinoma 

tumors. Please contact David W. 

Bradley, PhD at 

bradleyda@nidcr.nih.gov for more 

information. 

Dated: March 1, 2010. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2010–4761 Filed 3–4–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Long Acting Ophthalmic Analgesic Eye 

Drops 

Description of Invention: This 

invention is directed to the discovery 

that resiniferatoxin (RTX) produces a 

three to four day analgesic effect when 

topically applied to the cornea. Efficacy 

for RTX as an effective analgesic has 

been demonstrated in vivo in rats. 

Importantly, unlike currently available 

analgesics, RTX left the blink reflex 

intact and did not impact mechanical 

sensitivity. RTX also did not impair 

epithelial wound healing and 

functioned without detectable damage 

to the cornea. 

RTX is a potent agonist of the 

transient receptor potential channel, 

subfamily V, member 1 (TRPV1). TRPV1 

is involved in pain sensation and is 

expressed only in select neurons. Unlike 

other local analgesics that target a wide 

breadth of neurons, RTX targets only 

those neurons that express TRPV1, 

leaving the important blink reflex and 

mechanical sensitivity of the eye 

unaffected. 

Applications: 

• An ophthalmic analgesic for postoperative eye pain. 

• An ophthalmic analgesic for acute 

or chronic eye injury. 

• Applicable to both human and 

veterinary patients. 

Advantages: 

• Both long lasting and reversible. 

• Does not impair epithelial wound 

healing, leaves the blink reflex intact, 

and functions without detectable 

damage to the cornea. 

Development Status: 

• Early stage. 

• Demonstrated efficacy in vivo in 

rats. 

Market: Twenty-six million people 

worldwide experience neuropathic 

pain, resulting in healthcare costs of 

over three billion dollars per year. 

Inventors: Michael J. Iadarola, 

Andrew J. Mannes, Jason M. Keller, 

Kendall Mitchell, Brian D. Bates 

(NIDCR). 

Publication: In preparation. 

Patent Status: U.S. Provisional 

Application No. 61/247,881 filed 01 Oct 

2009 (HHS Reference No. E–117–2009/ 

0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Charlene Sydnor, 

PhD; 301–435–4689; 

sydnorc@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Dental and 

Craniofacial Research, Laboratory of 

Sensory Biology, Neurobiology and Pain 

Therapeutics Section, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize this technology. Please 

contact David W. Bradley, PhD at 301– 

402–0540 or bradleyda@nidcr.nih.gov 

for more information. 

Novel Compositions for Use as Bone 

Scaffolds and Enhancers of Bone 

Regeneration 

Description of Invention: This 

invention is directed to the discovery 

that a mixture of an organic polymer 

and inorganic particles may hold 

therapeutic utility as a biomaterial for 

artificial bone scaffolds, injectable bonefilling materials, and enhancement of 

new bone generation. This composition 

has demonstrated utility in vivo in 

mice. 

The inventors have discovered a 

means of producing a stably 

homogenous mixture of the organic 

polymer and inorganic particles by 

crosslinking the two components. In 

contrast to current technologies, this 

invention not only imparts sufficient 

mechanical and load-bearing strength 

but also provides a suitable 

environment for new bone formation. 

Importantly, since the chemical reaction 

applied to make this biomaterial does 

not produce any harmful molecules or 

heat, it can be used in an injectable 

form. Bone formation or replacement is 

often a desired therapy for bone loss or 

defects due to fractures or bone 

degenerative diseases. 

Applications: 

• Injectable bone-filling materials. 

• Artificial bone sponge for bone 

defect. 

• Artificial bone sponge for bone cell 

culture in bone and mineralization 

research. 

Advantages: 

• Combines bone-like strength and a 

suitable environment for new bone 

formation 

• Injectable. 

Development Status: 

• Early stage. 

• Tested in vivo in mice. 

Market: According to 

Freedoniagroup.com, the US orthopedic 

implant market was $14.3 billion in 

2007 and is expected to grow 8.9 

percent annually through 2012. (http:// 

www.freedoniagroup.com/OrthopedicImplants.html, accessed December 2, 

2009.) 

Inventors: EunAh Lee and Pamela 

Robey (NIDCR) et al. 

Publication: In preparation. 

Patent Status: 


erowe on DSK5CLS3C1PROD with NOTICES
10286 Federal Register / Vol. 75, No. 43 / Friday, March 5, 2010 / Notices 

• U.S. Provisional Application No. 

61/004,940 filed 30 Nov 2007 (HHS 

Reference No. E–042–2007/0–US–01). 

• PCT Application No. PCT/US2008/ 

012064 filed 22 Oct 2008, which 

published as WO 2009/073068 on 11 

Jun 2009 (HHS Reference No. E–042– 

2007/0–PCT–02). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Charlene Sydnor, 

PhD; 301–435–4689; 

sydnorc@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Dental and 

Craniofacial Research, Craniofacial and 

Skeletal Diseases Branch, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize this technology. Please 

contact David W. Bradley, PhD at 301– 

402–0540 or bradleyda@nidcr.nih.gov 

for more information. 

Gamma Substituted Peptide Nucleic 

Acids 

Description of Invention: PNAs are 

nuclease/protease resistant synthetic 

nucleic acid analogs capable of forming 

very stable and highly sequence-specific 

complexes with DNA. Scientists at the 

NIH have developed novel peptide 

nucleic acids (PNAs) that contain a 

unique sidechain that can attach any 

small ligand, peptide, or carbohydrate to 

complementary DNA for rapid 

optimization. This invention could 

revolutionize the way in which 

multivalent display is used in research 

as well as help develop new 

medications. 

Applications: 

• Controlled interactions ensure only 

a single stoichiometry is attained. 

• Simple access to a wide range of 

multivalent platforms. 

Development Status: Early stage. 

Inventors: Daniel Appella (NIDDK) 

Patent Status: U.S. Provisional 

Application No. 61/162,175 filed 20 Mar 

2009 (HHS Reference No. E–151–2009/ 

0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Charlene Sydnor, 

PhD; 301–435–4689; 

sydnorc@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Diabetes and 

Digestive and Kidney Diseases, 

Laboratory of Bioorganic Chemistry, 

Drug-Receptor Interactions Section, is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize this 

technology. Please contact Dr. Daniel 

Appella at appellad@niddk.nih.gov for 

more information. 

Use of Modified Peptide Nucleic Acids 

for Visualizing DNA 

Description of Technology: The 

compounds described in this technology 

may be useful in the development of 

nucleic acid detection kits for various 

pathogens. 

Technologies for genomic detection 

most commonly use DNA probes to 

hybridize to target sequences, and 

require the use of Polymerase Chain 

Reaction (PCR) to amplify target 

sequences. Replacing the DNA probe 

with peptide nucleic acid (PNA) can 

greatly eliminate the need for PCR 

because the binding strength of PNAs to 

complementary DNA is stronger than 

DNA binding to complementary DNA. 

In addition, PNAs are nuclease and 

protease resistant, and form very stable 

and highly sequence-specific complexes 

with DNA. 

This technology describes a method of 

making pure enantiomers of trans-tertbutyl-2-aminocyclopentylcarbamate 

(tcycp) and methods of modifying PNAs 

by incorporating tcycp compounds into 

the PNA. This technology may also be 

practical for detecting infectious agents 

such as anthrax, avian flu, tuberculosis 

(TB), severe acute respiratory syndrome 

(SARS), human papilloma virus (HPV) 

and human immunodeficiency virus 

(HIV). 

Applications: 

• Very stable diagnostic method to 

detect nucleic acids without using 

Polymerase Chain Reaction (PCR). 

• Binding to complementary DNA 

can be seen by eye. 

• Visual detection of anthrax has 

been shown. 

• Useful for outside of a laboratory 

environment. 

Development Status: Early stage. 

Inventors: Daniel Appella et al. 

(NIDDK). 

Patent Status: U.S. Patent Application 

No. 12/441,925 filed 19 Mar 2009 (HHS 

Reference No. E–308–2006/2–US–02). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Charlene Sydnor, 

PhD; 301–435–4689; 

sydnorc@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Diabetes and 

Digestive and Kidney Diseases, 

Laboratory of Bioorganic Chemistry, 

Drug-Receptor Interactions Section, is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize this 

technology. Please contact Dr. Daniel 

Appella at appellad@niddk.nih.gov for 

more information. 

Dated: March 1, 2010. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2010–4759 Filed 3–4–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Methods To Increase Stability of 

Recombinant Vaccinia-Vectored 

Vaccines and Increase Expression of a 

Foreign Gene Inserted in Such Vaccines 

Description of Invention: The 

technology offered for licensing is in the 

field of vaccinia-based recombinant 

vaccines. In particular the invention 

relates to methods of stabilizing the 

recombinant virus, thus resulting in 

efficient production of the vaccine and 

efficient expression of the inserted gene. 

Stabilization of the recombinant virus is 

achieved by the insertion of the 

exogenous gene into an intergenic 

region (IGR) of the viral genome (i.e. 

Modified Vaccinia Ankara, MVA), 

where the IGR is flanked by open 

reading frames of conserved poxvirus 

genes. Furthermore, the invention 

relates to plasmids vectors useful to 


erowe on DSK5CLS3C1PROD with NOTICES